Oncothyreon to Present at Cowen and Company 36th Annual Health Care Conference

SEATTLE, March 01, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Julie M. Eastland, President and Chief Financial Officer and Vice President, Corporate Development, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m. Eastern Time in New York.

A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the “News & Events” section.

About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor. We are developing preclinical product candidates in oncology and immune-oncology using our protocell technology. For more information, visit www.oncothyreon.com.


Investor Relations:
Julie Rathbun
Rathbun Communications

Media Relations:
Kelly France, Ph.D.

ONCOTHYREON INC., 2601 Fourth Avenue, Suite 500, Seattle, WA 98121
Tel: (206) 801-2100   Fax:  (206) 801-2101